**Core tip:** Gestational Hypertension (GHTN) can increase risk of fetal and neonatal morbidity and mortality. Many environmental, nutritional and genetic factors are related to the development of GHTN. Among them, Epidermal Growth Factor Receptor (EGFR) has been found to contribute to arterial hypertension. It is thus plausible that Single nucleotide polymorphisms (SNPs) in EGFR gene would be associated with the development of GHTN in women with GDM. This pilot study indicated that EGFR rs17337023 polymorphism may not be involved in the pathophysiology of GHTN in GDM positive females in a local population. Further large-scale studies should explore SNPs in EGFR and other genes in this regard.

INTRODUCTION
============

Gestational diabetes mellitus (GDM), defined as any degree of glucose intolerance with onset or first recognition during pregnancy\[[@B1],[@B2]\], is a significant risk factor for maternal development of a hypertensive pregnancy disorder (HPD)\[[@B3]-[@B5]\]. Up to 10% of all pregnancies are complicated by HPDs\[[@B6],[@B7]\], especially in cases with pre-existing GDM\[[@B8]\]. One type of HPD, Gestational Hypertension (GHTN) occurs in 1.8%-4.4% of pregnancies\[[@B9]\]. GHTN is defined as blood pressure (BP) that reaches ≥ 140/90 mmHg for the first-time during pregnancy (after 20 wk gestation), without proteinuria. BP normalizes by 12 week postpartum\[[@B10]\]. Complications of GHTN include increased risk for fetal death and severe neonatal morbidity and mortality\[[@B11]\]. Hypothesized mecha-nisms of HPD development include dysfunction of the placenta, endothelium or lipid metabolism, as well as inflammatory states\[[@B12]\]. However, it is being increasingly established that genetic factors also contribute towards HPDs\[[@B13]\].

Single nucleotide polymorphisms (SNPs) have been a particular focus in genetic mechanisms leading to HPD\[[@B14]\]. SNPs such as NOS SNP rs2070744\[[@B15]\], APM1 SNP rs1501299\[[@B16]\], CYP19A1 SNP rs700158\[[@B17]\], KDR SNP rs2071559\[[@B18]\] and HSD11B1 rs846910\[[@B19]\], have been found to be associated with HPDs. The epidermal growth factor receptor (EGFR) is a single chain transmembrane protein of the ErbB family of receptor tyrosine kinases, which is activated following binding with peptide growth factors of the EGF-family of proteins\[[@B20]\]. The functions of EGFR include inducing cell growth and differentiation\[[@B21]\]. EGFR is abundantly expressed in the vascular wall and myocardium, and is thought to be linked to arterial hypertension, possibly by produc-ing vasoconstriction and renal Na^+^ retention\[[@B22]\]. Apart from its normal EGF Ligands, EGFR also undergoes transactivation by vasoactive substances such as catecho-lamines\[[@B23]\] and aldosterone\[[@B24]\]. The EGFR SNP rs17337023 (T \> A), located on Exon 16 with a global variant allele frequency of 0.456\[[@B25]\], is associated with chronic infla-mmation, which may lead to vascular damage and hypertension\[[@B26],[@B27]\]. Given the mechanistic link of EGFR to BP regulation, we decided to conduct a pilot study to explore any association of SNP rs17337023 with the development of GHTN in pregnant females with GDM.

MATERIALS AND METHODS
=====================

In a case-control study, *n* = 202 pregnant women at 28 wk of gestation with GDM were recruited. The study was conducted at Aga Khan University and Jinnah Postgraduate Medical Center during the period of January 2017 till August 2018. The sample size was calculated using the Open-Epi website\[[@B28]\], with a confidence level of 95%, power of 80%, least extreme odds ratio (OR) of 2 and a pregnancy hypertension prevalence of 8% taken according to previously published data sources\[[@B29]\]. The minimum sample size calculated for this research was *n* = 106. The institutional ethics committee approved the research protocol (Ref \# 4523-BBS-ERC-16) (REF: No.F.2-81/GENL-2017-IRB/15107/JPMC). GDM was diagnosed by means of a 75-g 2-h oral glucose tolerance test, as per the criteria set by the IADPSG\[[@B30]\]. All study subjects gave a written informed consent followed by weight and body mass index (BMI) assess-ment based on South Asian criteria for BMI values \[normal weight (BMI 18-22.9 kg/m^2^), and obese (BMI ≥ 26kg/m^2^)\]\[[@B31]\]. BP assessment was done following the latest European Society of Cardiology and the European Society of Hypertension task force guidelines\[[@B32],[@B33]\], (Normal BP \< 139/85 mmHg and Hypertension \> 139/85 mmHg). Subjects diagnosed with GHTN were subsequently being treated by antihypertensive medication. Any individual with a history of pre-existing diabetes, or any inflamm-atory condition, taking oral contraception or hormonal support, was not included in this study. Based on these measurements, grouping of study subjects was done as follow: (A) Normotensive (*n* = 80); (B) Hypertensive (*n* = 122) (on diet or medication).

Ten milliliters of venous blood were collected from each subject. DNA was extracted from whole blood by Qiagen DNA extraction kit (Cat. \#51185, Valencia, CA, United States). The quantification of extracted DNA was performed by measuring the ultraviolet absorbance of the samples using a Nanodrop-ND1000 (Thermo Fisher Scientific, Waltham, MA). The absorbance ratio (A280/A260) was determined for 2 μL samples using ND-1000 V3.8.1 software (Thermo Fisher Scientific, Waltham, MA). A ratio of approximately 1.8 was considered acceptable for confirming the purity of extracted DNA. Furthermore, around 10% of samples were confirmed on gel electro-phoresis by running 1 μL of sample in a 1% agarose gel against a 1 kb ladder. Tetra arms polymerase chain reaction (PCR) was performed using the Ruby Taq PCR Master mix 2X (Cat. \#71191, Affymetrix, United States) as per the manufacturer's instructions. PCR products were electrophoresed in a 2% agarose gel. Genotyping quality control was performed in 10% of the samples by duplicate checking (rate of concordance in duplicates was \> 99 %). The following primer set was used for gene amplification: Statistical analyses were conducted using the IBM Statistical Package for the Social, Sciences (IBM SPSS version 21; IBM Corp Inc, Armonk, NY). Descriptive analysis was applied, and data was expressed either as mean ± standard deviation or absolute number and percentage. SNP data was analysed for genotype and allele frequency determination by applying chi-squared statistics. In all situations a *P* value of \< 0.05 was considered significant. The statistical analyses for this study were performed and reviewed by Syed Adnan Ali (PhD. Statistics) of the University of Karachi.

RESULTS
=======

The detailed results are shown in Table [1, 2](#T1){ref-type="table"} and Figure [1](#F1){ref-type="fig"}. All study subjects were age-matched and therefore, no difference was observed in relation to age of the study subjects (*P* \> 0.05). Body fat percentage was significantly higher in hypertensive females as compared to normotensive subjects (*P* \< 0.05). Similarly, systolic and diastolic BP among were significantly higher in hypertensive group than the normo-tensive group (*P* \< 0.05). 90% of the hypertensive females practiced sedentary lifestyle versus 17.7% normotensive females (*P* \< 0.05).

###### 

Polymerase chain reaction primers details

  **Gene**                                               **Primers**                                 **Base pairs**   **PCR cycle**            **Amplicon Size**
  ------------------------------------------------------ ------------------------------------------- ---------------- ------------------------ -----------------------------------------
  Epidermal growth factor receptor (EGFR) rs17337023     Forward outer: ATTAACCACCAATCCAACATCCAGAC   26               67 °C; 30 s; 30 cycles   T allele 180; C allele 271; Control 406
  Reverse outer: CTTTCCCTCCACTGAGGACAAAGTT               25                                                                                    
  Forward inner (A allele): TCTCTTTCACTTCCTACAGATGCTCA   26                                                                                    
  Reverse inner (T allele): AGCCTTCAAGACCTGGCGCA         20                                                                                    

PCR: Polymerase chain reaction.

![Gel Electrophoresis of epidermal growth factor receptor samples 1 to 8 cases and 1 to 9 Controls. B is blank, and M is the 100bp ladder. Tetra arms control band is visible at 406bp; C allele at 271bp and T allele at 180bp.](WJD-10-396-g001){#F1}

###### 

Descriptive statistics and genotype frequency of study subjects

                                    **Hypertensive pregnant case (*n* = 122)**   **Normotensive pregnant control (*n* = 80)**   ***P*-value**
  --------------------------------- -------------------------------------------- ---------------------------------------------- ---------------
  Age (Yr)                          30.55 ± 8.05                                 29.13 ± 10.19                                  0.054
  Weight (kg)                       77.56 ± 16.88                                69.24 ± 11.07                                  0.025
  Body Fat %                        35.138 ± 4.29                                25.01 ± 8.28                                   0.000
  Waist circumference (cm)          104.50 ± 12.09                               86.92 ± 12.03                                  0.000
  Systolic blood pressure (mmHg)    131.76 ± 13.04                               122.02 ± 8.27                                  0.000
  Diastolic blood pressure (mmHg)   85.88 ± 8.45                                 73.31 ± 11.27                                  0.000
  Walk                                                                                                                          
  None                              90.1%                                        17.7%                                          0.000
  30 min/3 days week                7.9%                                         74.2%                                          
  30 min/5 days week                2.0%                                         8.1%                                           
  Genotype frequency                                                                                                            
  EGFR rs17337023 polymorphism                                                                                                  
  AA                                30                                           19                                             0.079
  AT                                56                                           48                                             
  TT                                36                                           13                                             
  Allele Odds Ratio                                                                                                             
  Allele A                          1.282 \[0.860-1.912\]                        0.219                                          
  Allele T                          0.780 \[0.523-1.163\]                        0.221                                          

Data presented as Mean ± SD and percentages. In all cases a *P* value of \< 0.05 was considered significant. Hardy-Weinberg Equilibrium (HWE) for case *P* = 0.378 and control *P* = 0.064, Where EGFR is epidermal growth factor receptor.

Overall EGFR rs17337023 polymorphism genotype frequency was similar in both the normotensive and hypertensive groups, with the heterozygous AT genotype showing predominance in both groups. Furthermore, the OR for A allele was 1.282 (*P* = 0.219) and for T allele was 0.780 (*P* = 0.221) in this study.

DISCUSSION
==========

The developmental causes of GHTN in women with pre-existing GDM is poorly understood and it is possible that genetic factors such as SNPs may play a role. Many studies have demonstrated associations of certain SNPs with development of HPDs. Our objective was to investigate whether the EGFR SNP rs17337023 displayed any significant association with the occurrence of GHTN in pregnant women with GDM. However, the findings of our study showed that the frequency of the rs17337023 genotype was not significantly different in the two groups. Furthermore, the OR for the A and T alleles were also non-significant. These results suggest that the SNP rs17337023 does not play any major role in the pathophysiology of GHTN in GDM.

There are possible explanations for the lack of any significant association. The study proposing mechanisms linking EGFR to arterial hypertension does so primarily on the basis of results obtained from experimenting using animal models, and voices uncertainties about its applicability to humans\[[@B22]\]. Moreover, apart from Rheumatoid Arthritis, the SNP rs17337023 has been shown to have no significant association with pathologies such as Gastric Carcinoma\[[@B34]\] and Nasopharyngeal Carcinoma\[[@B35]\]. This suggests that the function of EGFR is not altered significantly enough due to the SNP rs17337023 mutation to cause any major pathological state. It is possible, however, that other EGFR SNPs may indeed be associated with GHTN in women with GDM.

Additionally, since the sample for our pilot study consisted of 202 women from Pakistan, it is possible that the results may show greater significance if the study were replicated in another population with a larger sample size. The lack of association between the EGFR SNP rs17337023 served to suggest that the EGFR gene may not be involved in the pathophysiology of GHTN in the case of pre-existing GDM. Our study was limited by the inability to recruit a larger sample size due to cultural beliefs and barriers towards participation in genetic studies. Moreover, the group of women with GHTN were not managed uniformly in terms of diet and antihypertensive medi-cations. Nevertheless, the rs17337023 polymorphism was in Hardy-Weinberg Equilibrium for cases and controls, suggesting the randomness of the sample as a strength of our study.

This pilot study indicates that polymorphisms in rs17337023 may not be involved in the pathophysiology of gestational hypertension in gestational diabetes *via* inflammatory cascade mechanism. Further large-scale studies should explore polymorphism in epidermal growth factor receptor and other genes in this regard.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Pregnancy induced hypertension and diabetes are an increasing threat to the wellbeing of both mother and the baby. The basic pathophysiological link to disease predisposition is attributed to the functionality of epidermis and angiogenesis. Several genetic studies have provided evidence that epidermal growth factor dysfunction can lead to hypertension and its complications in preg-nancy.

Research motivation
-------------------

Materno-fetal mortality is on the rise in lower middle income countries; predominantly due to lack of primary prevention of non-communicable diseases. This led us to investigate one of the route cause *i.e*. genetic modification as a risk for development of disease.

Research objectives
-------------------

Explore any association of SNP rs17337023 with the development of gestational hypertension in pregnant females with gestational diabetes.

Research methods
----------------

A case-control study was conducted recruiting 202 pregnant women at 28 wk of gestation. Their blood pressure, blood glucose levels were measures and genotyping of EGFR SNP rs17337023 was performed via tetra arms PCR.

Research results
----------------

No difference was seen in the EGFR rs17337023 polymorphism genotype frequency among both normotensive and hypertensive groups in this study.

Research conclusions
--------------------

This pilot study indicates that polymorphisms in rs17337023 may not be involved in the pathophysiology of gestational hypertension in gestational diabetes. Further large-scale studies should explore polymorphism in epidermal growth factor receptor and other genes in this regard.

Research perspectives
---------------------

This study has shown some negative results linking a specific area of the gene EGFR; however, it should be noted that other factors may also be in play such as obesity and family history that can be a contributing factor along with genetic predisposition for hypertension. This opens up new avenues for researchers to perform prospective studies to identify the causal link between genetic and environmental factors.
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